Table 3.

Summary of the Endocrine Therapeutics for Gynecological Malignant Tumors in Hemodialysis Patients

Medication	Molecular Mass (Da)	Elimination	Half-Life (h)	Dose Reduction in Hemodialysis Patients	Safety	Administration in Relation to Hemodialysis Session	Literature
Anastrozole	293.4	85% with faeces, 11% with urine	41	No dose adjustment required	Safe	After HD	[24]
Letrozole	285.3	Primarily with liver	42	No dose adjustment required	Safe	No data	[61]
Exemestane	296.4	1% with urine	24	No data	No data	No data	[62]